Establishment Labs (NASDAQ:ESTA) Stock Price Down 6.7%

Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA - Get Free Report) traded down 6.7% during mid-day trading on Wednesday . The company traded as low as $49.18 and last traded at $50.33. 130,512 shares changed hands during trading, a decline of 68% from the average session volume of 402,328 shares. The stock had previously closed at $53.94.

Analyst Ratings Changes

ESTA has been the subject of several analyst reports. Stephens reaffirmed an "overweight" rating and set a $47.00 price target on shares of Establishment Labs in a research note on Thursday, January 11th. JPMorgan Chase & Co. lifted their target price on Establishment Labs from $46.00 to $53.00 and gave the stock an "overweight" rating in a report on Thursday, February 29th. Mizuho upped their price target on Establishment Labs from $50.00 to $65.00 and gave the company a "buy" rating in a research report on Monday, April 1st. Finally, Citigroup raised their price objective on Establishment Labs from $49.00 to $60.00 and gave the stock a "buy" rating in a research report on Wednesday, April 3rd. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $55.00.

Establishment Labs Trading Down 5.0 %

The company has a debt-to-equity ratio of 10.26, a current ratio of 3.06 and a quick ratio of 1.67. The firm has a market cap of $1.41 billion, a price-to-earnings ratio of -16.86 and a beta of 1.23. The firm's fifty day moving average is $50.27 and its 200-day moving average is $37.38.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last announced its quarterly earnings data on Wednesday, February 28th. The company reported ($0.79) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.95) by $0.16. Establishment Labs had a negative return on equity of 357.81% and a negative net margin of 47.53%. The company had revenue of $31.60 million for the quarter, compared to the consensus estimate of $31.44 million. During the same period in the previous year, the business earned ($0.55) EPS. The firm's revenue was down 27.9% compared to the same quarter last year. Equities analysts anticipate that Establishment Labs Holdings Inc. will post -1.63 earnings per share for the current year.

Institutional Investors Weigh In On Establishment Labs

Institutional investors and hedge funds have recently made changes to their positions in the business. Baker Avenue Asset Management LP bought a new stake in shares of Establishment Labs during the 3rd quarter valued at about $59,000. Clear Street Markets LLC bought a new stake in shares of Establishment Labs during the 3rd quarter valued at about $88,000. FNY Investment Advisers LLC bought a new stake in shares of Establishment Labs during the 4th quarter valued at about $93,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Establishment Labs by 67.2% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,591 shares of the company's stock valued at $119,000 after purchasing an additional 1,845 shares in the last quarter. Finally, SG Americas Securities LLC bought a new position in Establishment Labs in the fourth quarter worth approximately $120,000. Institutional investors own 72.91% of the company's stock.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.